Entera Bio Ltd. - (ENTX) closed at $3.11 on November 13, 2026, down 3.4% from the previous close, on volume of 151,752 shares (30-day average 494,390).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 13, 2026 | Calendar Call Spread | 20-Nov : 18-Dec-26 3 C | 252 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Entera Announces Third Quarter 2026 Financial Results and Business Updates
Globe Newswire (Fri, 6-Nov 4:15 PM ET)
Globe Newswire (Tue, 27-Oct 8:00 AM ET)
Globe Newswire (Tue, 13-Oct 7:00 AM ET)
Globe Newswire (Thu, 8-Oct 8:00 AM ET)
Globe Newswire (Tue, 6-Oct 8:00 AM ET)
Correction: Entera to Participate in Upcoming Fall Investor Conferences
Globe Newswire (Thu, 27-Aug 9:44 AM ET)
Entera to Participate in Upcoming Fall Investor Conferences
Globe Newswire (Thu, 27-Aug 8:00 AM ET)
Globe Newswire (Tue, 18-Aug 8:00 AM ET)
Market Chameleon (Mon, 27-Jul 5:52 AM ET)
ENTX Secures $275 Million Oversubscribed Private Placement to Fully Fund Phase 3 Trials Through 2030
Market Chameleon (Mon, 27-Jul 5:19 AM ET)
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Entera Bio Ltd. - trades on the NASDAQ stock market under the symbol ENTX.
As of November 13, 2026, ENTX stock price declined to $3.11 with 151,752 million shares trading.
ENTX has a beta of -0.14, meaning it tends to be less sensitive to market movements. ENTX has a correlation of 0.00 to the broad based SPY ETF.
ENTX has a market cap of $541.57 million. This is considered a Small Cap stock.
In the last 3 years, ENTX traded as high as $4.20 and as low as $.52.
The top ETF exchange traded funds that ENTX belongs to (by Net Assets): IZRL.
ENTX has outperformed the market in the last year with a return of +13.5%, while the SPY ETF gained +13.4%. In the last 3 month period, ENTX beat the market returning +8.4%, while SPY returned -2.8%. However, in the most recent 2 weeks ENTX has underperformed the stock market by returning -2.8%, while SPY returned -0.2%.
ENTX support price is $3.06 and resistance is $3.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENTX shares will trade within this expected range on the day.
